Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa
Christian M Gill, David P. Nicolau, Elif Aktaş, et al.
Journal of Antimicrobial Chemotherapy (2022) Vol. 78, Iss. 1, pp. 252-256
Open Access | Times Cited: 9

Showing 9 citing articles:

Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 135
Resistance in Pseudomonas aeruginosa: A Narrative Review of Antibiogram Interpretation and Emerging Treatments
F Giovagnorio, Andrea De Vito, Giordano Madeddu, et al.
Antibiotics (2023) Vol. 12, Iss. 11, pp. 1621-1621
Open Access | Times Cited: 24
Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa
Andrew J Fratoni, Matthew Gethers, David P. Nicolau, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 1, pp. 33-42
Closed Access | Times Cited: 4
Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye
Ecem Büyükyanbolu, Leyla Genc, Elizabeth A Cyr, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 9, pp. 1787-1794
Closed Access | Times Cited: 3
Assessing the in vivo efficacy of rational antibiotics and combinations against difficult-to-treat Pseudomonas aeruginosa producing GES β-lactamases
Yasmeen Abouelhassan, Christian M Gill, David P. Nicolau
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 8, pp. 1843-1847
Open Access | Times Cited: 8
In Vitro Activity of Ceftolozane-Tazobactam against Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa Obtained from Blood Cultures from Sentinel Public Hospitals in South Africa
Olga Perovic, Ashika Singh-Moodley, Michelle Lowe
Antibiotics (2023) Vol. 12, Iss. 3, pp. 453-453
Open Access | Times Cited: 7
Within-host transition to GES-55 during a GES-6-producing Serratia marcescens outbreak: Emergence of ceftazidime-avibactam resistance and increased susceptibility to carbapenems
Sergio García‐Fernández, Jorge Rodríguez-Grande, María Siller‐Ruiz, et al.
International Journal of Antimicrobial Agents (2024) Vol. 64, Iss. 2, pp. 107257-107257
Closed Access | Times Cited: 2
Not all carbapenem-resistant Pseudomonas aeruginosa strains are alike: tailoring antibiotic therapy based on resistance mechanisms
Marco Falcone, Valentina Galfo, Giusy Tiseo
Current Opinion in Infectious Diseases (2024) Vol. 37, Iss. 6, pp. 594-601
Open Access
Progress and New Challenges in Combatting the Threat of Antimicrobial Resistance: Perspective From an Infectious Diseases Pharmacist
Ryan K. Shields
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 2, pp. 303-306
Open Access | Times Cited: 1
Page 1

Scroll to top